Everolimus-based immunosuppressive regimens in lung transplant recipients: Impact on CMV infection

Antiviral Research

Volumn 113, Issue , 2015, Pages 19-26

  Rittà, Massimo ^a,b   Costa, Cristina ^a,b   Solidoro, Paolo ^a   Sidoti, Francesca ^a,b   Libertucci, Daniela ^a   Boffini, Massimo ^b   Rinaldi, Mauro ^b   Baldi, Sergio ^a   Cavallo, Rossana ^a,b  

^a CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Cytomegalovirus (CMV); Everolimus (EVR); Immunosuppression; Lung transplantation (LT); Opportunistic infections

Indexed keywords

ACICLOVIR; AZATHIOPRINE; CYCLOSPORIN A; EVEROLIMUS; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; VALGANCICLOVIR; ANTIVIRUS AGENT; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; DRUG SUBSTITUTION; FEMALE; FOLLOW UP; GRAFT INFECTION; GRAFT RECIPIENT; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INFECTION RISK; LUNG GRAFT REJECTION; LUNG INFECTION; LUNG LAVAGE; LUNG TRANSPLANTATION; MALE; OPPORTUNISTIC INFECTION; PROSPECTIVE STUDY; SYSTEMIC DISEASE; VIREMIA; VIRUS LOAD; ADOLESCENT; ANALOGS AND DERIVATIVES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG EFFECTS; ISOLATION AND PURIFICATION; LUNG; LUNG DISEASES; MIDDLE AGED; PHYSIOLOGY; VIROLOGY; YOUNG ADULT;

CYTOMEGALOVIRUS;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG; LUNG DISEASES; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; SIROLIMUS; TRANSPLANT RECIPIENTS; VIRAL LOAD; VIREMIA; YOUNG ADULT;

EID: 84912034783     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2014.10.016     Document Type: Article

References (23)

1. Boffini, M., Sansone, F., et al., 2009. Does everolimus associated with a low dose of cyclosporine in long-term cardiac transplant recipients improve renal function? Initial experience. Transplant. Proc. 41 (4), 1349-1352.
2. Brennan, D.C., Legendre, C., et al., 2011. Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials. Am. J. Transplant. 11 (11), 2453-2462.
3. Costa, C., Curtoni, A., et al., 2013. Detection of human cytomegalovirus in transbronchial biopsies from lung transplant recipients. Arch. Virol. 158 (7), 1461-1465.
4. Costa, C., Libertucci, D., et al., 2007. Rapid shell vial culture for the detection of respiratory viruses from bronchoalveolar lavage in immunocompromised patients. Panminerva Med. 49 (1), 1-6.
5. Costa, C., Saldan, A., et al., 2012. The lack of cytomegalovirus-specific cellular immune response may contribute to the onset of organ infection and disease in lung transplant recipients. Int. J. Immunopathol. Pharmacol. 25 (4), 1003-1009.
6. de Pablo, A., Santos, F., et al., 2013. Recommendations on the use of everolimus in lung transplantation. Transplant. Rev. (Orlando) 27 (1), 9-16.
7. Eid, A.J., Razonable, R.R., 2010. New developments in the management of cytomegalovirus infection after solid organ transplantation. Drugs 70 (8), 965-981.
8. Eisen, H.J., Tuzcu, E.M., et al., 2003. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N. Engl. J. Med. 349 (9), 847-858.
9. Ferrer, I.R., Wagener, M.E., et al., 2010. Cutting edge: Rapamycin augments pathogen-specific but not graft-reactive CD8+ T cell responses. J. Immunol. 185 (4), 2004-2008.
10. Fishman, J.A., Emery, V., et al., 2007. Cytomegalovirus in transplantation - challenging the status quo. Clin. Transplant. 21 (2), 149-158.
11. Gurk-Turner, C., Manitpisitkul, W., et al., 2012. A comprehensive review of everolimus clinical reports: a new mammalian target of rapamycin inhibitor. Transplantation 94 (7), 659-668.
12. Hill, J.A., Hummel, M., et al., 2007. A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus. Transplantation 84 (11), 1436-1442.
13. Imamura, T., Shiga, T., et al., 2012. Successful conversion to everolimus after cytomegalovirus infection in a heart transplant recipient. Int. Heart J. 53 (3), 199-201.
14. Kobashigawa, J., Ross, H., et al., 2013. Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation. Transpl. Infect. Dis. 15 (2), 150-162.
15. Nashan, B., Gaston, R., et al., 2012. Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients. Transplantation 93 (11), 1075-1085.
16. Roux, A., Mourin, G., et al., 2013. CMV driven CD8(+) T-cell activation is associated with acute rejection in lung transplantation. Clin. Immunol. 148 (1), 16-26.
17. Snydman, D.R., Limaye, A.P., et al., 2011. Update and review: state-of-the-art management of cytomegalovirus infection and disease following thoracic organ transplantation. Transplant. Proc. 43 (3 Suppl.), S01-S17.
18. Stewart, S., Fishbein, M.C., et al., 2007. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J. Heart Lung Transplant. 26 (12), 1229-1242.
19. Valantine, H., Zuckermann, A., 2005. From clinical trials to clinical practice: an overview of Certican (everolimus) in heart transplantation. J. Heart Lung Transplant. 24 (4 Suppl.), S185-S190, discussion S210-S181.
20. Vigano, M., Dengler, T., et al., 2010. Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study. Transpl. Infect. Dis. 12 (1), 23-30.
21. Vitko, S., Margreiter, R., et al., 2005. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am. J. Transplant. 5 (10), 2521-2530.
22. Webster, A.C., Lee, V.W., et al., 2006. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 81 (9), 1234-1248.
23. Zamora, M.R., Davis, R.D., et al., 2005. Management of cytomegalovirus infection in lung transplant recipients: evidence-based recommendations. Transplantation 80 (2), 157-163.